Financial Summary
For the nine months ended March 31, 2022

Temple University Health System Management Discussion and Analysis March 31, 2022

Overview

Temple University Health System ("TUHS") reported a net income of \$325,672,000 for the nine months ended March 31, 2022 versus a budgeted net income of \$31,257,000 resulting in a favorable budget variance of \$294,415,000. Operating income, which excludes investment income, changes in market value of equity securities, and other non-operating income, was \$91,628,000 versus budgeted operating income of \$17,273,000 resulting in a favorable budget variance of \$74,355,000. \$28,702,000 of Provider Relief Funds ("PRF") were recognized year-to-date in other revenue at Temple University Hospital, Inc. ("TUH, Inc."). Net income, excluding the gain on sale of Health Partners Plans, Inc. ("HPP"), was \$94,481,000.

Other investment income (loss) was unfavorable to budget (\$18,403,000) due to decreases in the market value of equity securities. Non-Operating income was favorable to budget \$238,463,000 due to the sale of HPP.

Actual versus Budget Summary

TUHS reported operating income of \$91,628,000 versus a budgeted operating income of \$17,273,000 for a favorable variance of \$74,355,000. These results were driven by favorable net patient service revenue, PRF revenue and the timing of recognition of Commonwealth reimbursement, partially offset by above budget operating expenses.

Healthcare Operations Performance:

Outpatient revenues were favorable to budget \$41,175,000 primarily as a result of the \$34,477,000 variance at TUH, Inc. TUH, Inc. outpatient revenue was above budget due to above budget surgeries as well as performance of the specialty and retail pharmacies. Favorable outpatient infusion volumes and revenue cycle performance were also significant drivers. While outpatient registrations, excluding Hospital Based visits ("HBB") were below budget, the variance was primarily related to low-dollar lab and procedures. Key operating indicators versus budget were as follows:

TUH, Inc.	Actual	Budget	\mathbf{V}	V%
Outpatient Surgeries	7,137	6,892	245	3.6%
Outpatient Registrations (Excl. HBB)	321,183	347,434	(26,251)	-7.6%
HBB Clinic Registrations	166,654	150,411	16,243	10.8%

In addition to TUH, Inc., outpatient revenue was favorable to budget \$6,698,000 at American Oncologic Hospital and Affiliates, (AOH, Inc.). Surgical procedures were above budget 7.4%, chemo infusions were above budget 19% and while radiation oncology procedures were slightly below budget at (0.6%), favorable patient mix drove revenue above budget.

Inpatient revenues were slightly behind budget at (\$2,596,000) or (0.4%), primarily as a result of the (\$2,699,000) or (5.8%) variance at AOH, Inc. TUH, Inc. inpatient revenue was tracking budget despite unfavorable discharges and surgeries, driven by favorable CMI and BMT program performance:

TUH, Inc.	Actual	Budget	\mathbf{V}	V%
Inpatient Discharges	24,978	25,908	(930)	-3.6%
CMI	1.98	1.96	0.02	1.0%
ED Inpatient Discharges	19,097	19,595	(498)	-2.5%
Inpatient Surgeries	6,014	6,685	(671)	-10.0%
Transplants	256	254	2	0.8%

Operating expenses were unfavorable to budget (\$46,538,000). Salaries expenses were above budget (\$32,355,000) due primarily to nursing costs driven by increased use of agency and overtime due to national labor shortages. Professional fees were also above budget (\$6,397,000) primarily due to nursing direct hire placement and legal fees. Unfavorable salaries and professional fees expenses were partially offset by below budget employee benefits expenses \$6,813,000, driven by lower core benefits and defined contribution retirement plan expenses.

Through March 31, 2022, TUHS cancer services contributed EBIDA of \$62,722,000 compared to a budget of \$35,979,000 for a positive budget variance of \$26,743,000.

Net Commonwealth Funding:

Net Commonwealth funding was favorable to budget \$67,380,000 primarily driven by recognition of \$54,049,000 of disproportionate share ("DSH") funding that is budgeted in June. If the budget was spread evenly over twelve months, DSH funding would be favorable to budget \$31,680,000 as of March 31, 2022. Additionally, one-time COVID DSH payments were received for both fiscal year 2021 and 2022.

Population Health Performance:

Population health activity consists partially of revenues earned through provider based pay-for-performance contracts coordinated by Temple Center for Population Health ("TCPH"). The second component of population health revenue is TUHS's risk arrangements. Population health revenue was unfavorable to budget by (\$14,243,000), primarily driven by unfavorable results in TUHS's risk arrangements driven by an earlier than anticipated closing of the sale of HPP as well as lower than budgeted performance post sale.

Other revenue was favorable to budget \$25,877,000 due to CARES Act Funding recognized of \$28,702,000.

Year over Year Summary

TUHS reported operating income of \$91,628,000 for the nine months ended March 31, 2022 compared to operating income of \$63,022,000 in the prior year. The increase of \$28,606,000 versus the prior year was primarily driven by increased outpatient revenues, Commonwealth funding, and physician revenues, partially offset by increased operating expenses.

Total net patient service revenue, excluding Commonwealth funding, increased by \$104,636,000, due to increases in outpatient revenue \$97,441,000 and physician revenue 17,689,000, partially offset by a decrease in inpatient revenue of (\$10,888,000).

Key operating indicators versus the prior year were as follows:

TUHS Consolidated	Actual	Prior Yr	V	V%
Inpatient				
Inpatient Discharges	27,570	30,078	(2,508)	-8.3%
CMI	1.97	1.91	0.06	3.1%
ED Inpatient Discharges	19,097	21,674	(2,577)	-11.9%
Inpatient Surgeries	7,327	7,621	(294)	-3.9%
Transplants	256	229	27	11.8%
Outpatient				
Outpatient Surgeries	9,634	8,877	757	8.5%
ED Visits	117,471	111,179	6,292	5.7%
Outpatient Registrations (Excl. HBB)	336,297	307,998	28,299	9.2%
HBB Clinic Registrations	166,654	116,434	50,220	43.1%
Physician Visits	818,352	759,838	58,514	7.7%

Net Commonwealth Funding:

Net Commonwealth funding increased by \$72,235,000 primarily due to the receipt of new fiscal year 2021 opioid use disorder funding that was not approved until early fiscal year 2022, along with receipt of additional opioid funding related to fiscal year 2022.

Population Health Performance:

Population health revenue decreased by (\$15,780,000) due to a decrease in revenue from TUHS's risk sharing arrangements.

Other revenue increased \$5,150,000 versus the prior year primarily due to higher Provider Relief Funds recognized in fiscal year 2022.

Operating expenses increased \$136,808,000 year-over-year. Salaries increased \$69,584,000, driven by higher nursing costs associated with increased agency usage and overtime as well as annual salary increases. Employee benefits increased \$12,005,000 due to higher medical, prescription, and retirement expenses. Professional fees increased \$9,746,000 due to an increase in IT spending. Supplies and pharmaceuticals increased by \$21,177,000, primarily related to increased outpatient pharmacy volumes.

Liquidity

Liquidity at March 31, 2022 was \$1,170,406,000 compared to \$888,469,000 at March 31, 2021 and \$973,907,000 at June 30, 2021. The increase of \$281,937,000 versus March 31, 2021 was primarily a result of the sale of HPP, strong operating performance, and increased Commonwealth funding during the past twelve months. These amounts were offset by \$93,620,000 of Medicare advances that were repaid and \$12,927,000 in payroll tax deferrals that were repaid. The increase of \$196,499,000 versus June 30, 2021 is primarily due to the sale of HPP, Opioid Use Disorder (OUD) and COVID funding received from the Commonwealth, partially offset by repayments of COVID related Medicare advances and employer payroll tax deferrals. Days cash on hand ("DCOH") at March 31, 2022 was 190 days compared to 157 at June 30, 2021 and 148 at March 31, 2021.

Consolidated Financial Management Report For the nine months ended March 31, 2022 Actual versus Budget

Temple University Health System Key Operating Indicators For the nine months ended March 31, 2022

	YTD	%	YTD	%	Variance
	Actual		Budget		
Patient Discharges:					
Inpatient Acute Discharges	27,570	75.4%	28,751	74.5%	(1,181)
Behavioral Health Discharges	1,157	3.2%	1,584	4.1%	(427)
Subtotal Acute Discharges (Med/Surg & Behavioral Hlth.)	28,727	78.6%	30,335	78.6%	(1,608)
CDU Observation Discharges	-	-	-	-	-
Non-CDU Observation Discharges	7,831	21.4%	8,252	21.4%	(421)
Subtotal Observation Discharges	7,831	21.4%	8,252	21.4%	(421)
Total Discharges including Observations	36,558	100.0%	38,587	100.0%	(2,029)
Births	1,481		1,667		(186)
Case Mix Index - Total	1.97		1.95		0.02
PATIENT LENGTH OF STAY - ALL EXCEPT BIRTHS					
Inpatient Acute Discharges	6.14		5.68		(0.46)
Behavioral Health LOS	27.26		20.24		(7.02)
CDU Observation LOS	-		-		-
Non-CDU Observation LOS	1.70		1.51		(0.19)
Patient Days Including Observation	214,082		207,796		6,286
Census Patient Days Including Observation Cases	214,862		205,179		9,683
Average Daily Census Including Observation	784		749		35
Staffed Beds (% Occupancy including Observations)	86.62%		82.72%		3.91%

Temple University Health System Key Operating Indicators For the nine months ended March 31, 2022

	YTD	%	YTD	%	Variance
	Actual		Budget		
Inpatient Acute Discharges - Payer Mix					
Medicaid	12,379	43.1%	11,797	38.9%	582
Medicare	11,730	40.8%	13,378	44.1%	(1,648)
Blue Cross	2,611	9.1%	2,956	9.7%	(345)
Managed Care	1,811	6.3%	1,705	5.6%	106
Other	196	0.7%	499	1.6%	(303)
Total Acute Discharges- All Except Births	28,727	100.0%	30,335	100.0%	(1,608)
EMERGENCY DEPARTMENT:					
Inpatient Discharges (admitted from ED)	19,097		19,595		(498)
Percentage of Acute Inpatient Discharges (admitted from ED)	69.3%		68.2%		1.1%
ED Visits	117,471		122,527		(5,056)
OPERATING ROOM:					
Inpatient	7,327		8,067		(740)
Outpatient	9,634		9,218		416
Total Operations	16,961	_	17,285		(324)
Transplants	256		254		2
Total Outpatient Registrations	502,951		550,702		(47,751)
FULL TIME EQUIVALENTS - TOTAL HEALTH SYSTEM					
Based on total paid hours	9,898		10,220		322
Based on total adjusted hours including contracted services, excluding residents	9,323		9,630		307

Temple University Health System
Operating Statement
(In thousands)
For the nine months ended March 31, 2022

10110 00110011144.04			Year-to-Date	
		Actual	Budget	Variance
REVENUES:	Line #		-	
Net patient service revenue:				
Inpatient	1	685,997	688,594	(2,596)
Outpatient	2	623,927	582,752	41,175
Physician revenue	3	182,585	177,103	5,482
Commonwealth reimbursement	4	332,371	201,615	130,756
Net patient service revenue before provision for doubtful accounts	5	1,824,880	1,650,064	174,817
Provision for doubtful accounts	6	613	(86)	698
Total Net Patient Service Revenue	7	1,825,493	1,649,978	175,515
Research Revenue	8	29,454	31,851	(2,397)
Population Health	9	13,223	27,466	(14,243)
Contribution Revenue	10	3,111	3,898	(787)
Other Revenue - F/S	11	49,093	23,216	25,877
Investment Income - Revenue	12	257	311	(55)
Total Revenues	13	1,920,631	1,736,721	183,910
EXPENSES:				
Salaries	14	816,030	783,675	(32,355)
Employee benefits	15	204,806	211,620	6,813
Professional fees	16	48,171	41,774	(6,397)
Faculty support	17	63,077	60	(63,017)
Supplies and pharmaceuticals	18	388,716	379,876	(8,841)
Purchased services and other expense	19	106,493	109,193	2,700
Maintenance	20	19,696	18,116	(1,580)
Utilities	21	16,015	17,031	1,016
Leases	22	10,811	10,622	(189)
Insurance	23	56,905	49,976	(6,929)
Depreciation and amortization	24	37,202	36,247	(955)
Interest	25	17,023	17,561	538
Assessment Programs	26	44,057	43,699	(358)
Total Expenses	27	1,829,003	1,719,448	(109,555 <u>)</u>
Operating Income(Loss)	29	91,628	17,273	74,355
Other investment income	30	(6,867)	11,536	(18,403)
Non operating income (loss)	31	240,911	2,448	238,463
Net Income (Loss)	32	325,672	31,257	294,415

UNAUDITED CONFIDENTIAL

Temple University Health System
Operating Statement
(In thousands)
For the nine months ended March 31, 2022

Actual	Year-to-Date Budget	!
Actual	Rudgot	
	Duuget	Variance
(9,595)	0	(9,595)
905	0	905
0	0	0
242	0	242
317,224	31,257	285,967
11,240	0	11,240
(4,579)	0	(4,579)
(425)	0	(425)
3,405	0	3,405
(5,204)	0	(5,204)
4,437	0	4,437
321,661	31,257	290,404
	4,437	4,437 0

Consolidated Financial Management Report For the nine months ended March 31, 2022 Year Over Year Comparison

	Year-to-Date				
		%	Prior Year	%	Prior Year
	Actual		Actual		Variance
Patient Discharges:					
Inpatient Acute Discharges	27,570	75.4%	30,078	80.1%	(2,508)
Behavioral Health Discharges	1,157	3.2%	1,138	3.0%	19
Subtotal Acute Discharges (Med/Surg & Behavioral Hlth.)	28,727	78.6%	31,216	83.1%	(2,489)
CDU Observation Discharges	-	-	503	1.3%	(503)
Non-CDU Observation Discharges	7,831	21.4%	5,823	15.5%	2,008
Subtotal Observation Discharges	7,831	21.4%	6,326	16.9%	1,505
Total Discharges including Observations	36,558	100.0%	37,542	100.0%	(984)
Births	1,481		1,682		(201)
Case Mix Index - Total	1.97		1.91		0.06
PATIENT LENGTH OF STAY - ALL EXCEPT BIRTHS					
Inpatient Acute Discharges	6.14		5.48		(0.66)
Behavioral Health LOS	27.26		22.79		(4.47)
CDU Observation LOS	-		1.52		1.52
Non-CDU Observation LOS	1.70		1.53		(0.17)
Patient Days Including Observation	214,082		200,471		13,611
Census Patient Days Including Observation Cases	214,862		204,308		10,554
Average Daily Census Including Observation	784		746		39
Staffed Beds (% Occupancy including Observations)	86.62%		82.96%		3.66%

			Year-to-Date		
		%	Prior Year	%	Prior Year
	Actual		Actual		Variance
Inpatient Acute Discharges - Payer Mix					
Medicaid	12,379	43.1%	13,174	42.2%	(795)
Medicare	11,730	40.8%	13,096	42.0%	(1,366)
Blue Cross	2,611	9.1%	2,948	9.4%	(337)
Managed Care	1,811	6.3%	1,677	5.4%	134
Other	196	0.7%	321	1.0%	(125)
Total Acute Discharges- All Except Births	28,727	100.0%	31,216	100.0%	(2,489)
EMERGENCY DEPARTMENT:					
Inpatient Discharges (admitted from ED)	19,097		21,674		(2,577)
Percentage of Acute Inpatient Discharges (admitted from ED)	69.3%		72.1%		(2.8)%
ED Visits	117,471		111,179		6,292
OPERATING ROOM:					
Inpatient	7,327		7,621		(294)
Outpatient	9,634		8,877		757
Total Operations	16,961		16,498		463
Transplants	256		229		27
Total Outpatient Registrations	502,951		424,432		78,519
FULL TIME EQUIVALENTS - TOTAL HEALTH SYSTEM					
Based on total paid hours	9,898		9,669		(230)
Based on total adjusted hours including contracted services, excluding residents	9,323		9,071		(252)

Temple University Health System
Operating Statement Year Over Year
(In thousands) For the nine months ended March 31, 2022

UNAUDITED CONFIDENTIAL

		Actual	Prior Year Actual	Prior Year Variance
REVENUES:	Line #			
Net patient service revenue:				
Inpatient	1	685,997	696,886	(10,888)
Outpatient	2	623,927	526,486	97,441
Physician revenue	3	182,585	164,896	17,689
Commonwealth reimbursement	4	332,371	248,237	84,134
Net patient service revenue before provision for doubtful accounts	5	1,824,880	1,636,505	188,376
Provision for doubtful accounts	6	613	218	395
Total Net Patient Service Revenue	7	1,825,493	1,636,723	188,770
Research Revenue	8	29,454	32,831	(3,377)
Population Health	9	13,223	29,002	(15,780)
Contribution Revenue	10	3,111	2,581	530
Other Revenue - F/S	11	49,093	43,943	5,150
Investment Income - Revenue	12	257	106	151
Total Revenues	13	1,920,631	1,745,186	175,445
EXPENSES:				
Salaries	14	816,030	746,446	(69,584)
Employee benefits	15	204,806	192,801	(12,005)
Professional fees	16	48,171	38,425	(9,746)
Faculty support	17	63,077	53,046	(10,031)
Supplies and pharmaceuticals	18	388,716	367,540	(21,177)
Purchased services and other expense	19	106,493	98,553	(7,940)
Maintenance	20	19,696	15,112	(4,584)
Utilities	21	16,015	14,539	(1,476)
Leases	22	10,811	10,635	(175)
Insurance	23	56,905	51,728	(5,177)
Depreciation and amortization	24	37,202	33,709	(3,493)
Interest	25 26	17,023	17,441	417
Assessment Programs		44,057	42,189	(1,868)
Total Expenses	27	1,829,003	1,682,164	(146,839)
Operating Income(Loss)	29	91,628	63,022	28,606
Other investment income	30	(6,867)	41,251	(48,118)
Non operating income (loss)	31	240,911	3,693	237,218
Net Income (Loss)	32	325,672	107,966	217,706

Temple University Health System
Operating Statement Year Over Year
(In thousands)
For the nine months ended March 31, 2022

UNAUDITED CONFIDENTIAL

		,	Year-to-Date			
		Actual	Prior Year Actual	Prior Year Variance		
OTHER CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS						
Unrestricted unrealized gain/loss	33	(9,595)	(2,064)	(7,530)		
Net asset released from restriction used for purchase of PPE	34	905	1,993	(1,088)		
Transfers from (to) affiliates	35	0	0	0		
Interfund Transfer	36	0	17	(17)		
Other comprehensive income pension	37	242	176	65		
TOTAL INCREASE (DECREASE) IN NET ASSETS WITHOUT DONOR RESTRICTIONS	38	317,224	108,088	209,137		
NET ASSETS WITH DONOR RESTRICTIONS						
Contribution income	39	11,240	4,111	7,130		
Net assets released from restrictions	40	(4,579)	(8,109)	3,530		
Net change in fair value of investments	41	(425)	2,779	(3,203)		
Investment income (loss)	42	3,405	2,246	1,159		
Change in value of beneficial interests	43	(5,204)	8,089	(13,294)		
TOTAL INCREASE (DECREASE) IN NET ASSETS WITH DONOR RESTRICTIONS	44	4,437	9,115	(4,678)		
TOTAL INCREASE (DECREASE) IN NET ASSETS		321,661	117,203	204,459		

Consolidated Statement of Cash Flows For the nine months ended March 31, 2022

Temple University Health System

TUHS Consolidated

Statement of Cash Flows

(In Thousands)

For the nine months ended March 31, 2022 and 2021

UNAUDITED CONFIDENTIAL

	2022	2021			2022	2021
OPERATING ACTIVITIES:			INVESTING ACTIVITIES:			
Increase in net assets from continuing operations	\$ 321,661	\$ 117,203	Decrease in restricted assets	\$	16,511	\$ 29,041
Adjustments to reconcile increase in net assets to			Purchases of property, plant and equipment		(54,951)	(21,095)
net cash (used in) provided by operating activities:			Purchases of investments		(418,426)	(61,567)
Net realized and unrealized gains on investments	(39,622)	(40,169)	Proceeds from sales of investments		176,783	42,667
Net realized and unrealized losses (gains) on beneficial interests			Proceeds from sale of equity method investment		298,279	-
in perpetual trusts and assets held by Episcopal Foundation			Proceeds from sales of fixed assets		53	1,190
and Fox Chase Cancer Center Foundation	5,204	(8,089)	Cash acquired from asset transfer			
Depreciation, amortization and accretion	36,992	33,476				
Intangible amortization	210	233	Net cash provided by (used in) investing activities		18,249	(9,764)
Amortization of bond premium, discount, debt issuance costs,						
and underwriter's discount	(1,239)	(1,277)	FINANCING ACTIVITIES:			
Allowance for doubtful accounts	(613)	(218)	Proceeds from contributions and investments restricted to			
Adjustment to funded status of pension and postretirement liabilities	(159)	(176)	property, plant and equipment and endowments		905	1,993
Adjustment to funded status of long-term disability liabilities	(83)	-	Repayment of long-term debt		(8,362)	(9,388)
Proceeds from contributions and investments restricted to			Repayment of capital lease obligations		(2,626)	(3,626)
property, plant and equipment and endowments	(905)	(1,993)	Refunding of equipment loans		(5,135)	-
Gain on disposal of fixed assets	(84)	(108)	Proceeds from issuance of long-term debt		5,135	-
Perpetually restricted gifts and donations received	(3,325)	553	Perpetually restricted gifts and donations received		3,325	(553)
Gain on sale of equity method investment	(231,191)	-				
Changes in operating assets and liabilities:			Net cash used in financing activities		(6,758)	(11,574)
Patient accounts receivable	(13,785)	(56,097)				
Other receivables	(194,649)	(149,892)				
Pledges receivable — net	(1,421)	396	NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS,			
Inventories and other current assets	(30,774)	(17,882)	AND RESTRICTED CASH		(83,063)	88,074
Expenditures reimbursable by research grants and awards	981	(1,104)				
Other assets	(7,327)	(7,707)	CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of year		547,433	612,821
Accounts payable	57,836	62,154				
Accrued expenses	9,628	30,291	CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of quarter	\$	464,370	\$ 700,895
Estimated settlements with third-party payors	(63,848)	(21,570)		_		
Self-insurance program receivables and liabilities	(13,340)	(179)	Cash and cash equivalents		448,513	678,715
Unexpended research grants and awards	(1,920)	707	Restricted cash included in assets limited as to use		15,857	22,180
Net change in operating lease right-of-use assets and liabilities	(24)	-	Total cash, cash equivalents, and restricted cash	\$	12122	\$ 700,895
Other liabilities	 77,243	170,860	_	_		
Net cash (used in) provided by operating activities	(94,554)	109,412				
()1	 \ //		_			

Consolidated Balance Sheet For the nine months ended March 31, 2022

Temple University Health System TUHS Consolidated Balance Sheet

(In Thousands) March

	March FY22	June FY21		March FY22	June FY21
ASSETS			LIABILITIES and NET ASSETS:		
CURRENT ASSETS:			CURRENT LIABILITIES:		
Cash and cash equivalents	448,513	533,231	Current portion of long-term debt	17.532	13.016
Patient accounts receivable, net	272,903	258,505	Lines of credit	0	0
Other receivables, including current portion pledges	294,018	97,784	Cash overdraft	0	0
Due from affiliates - Short term	0	0		0	0
Due from Temple University	1,056	1,570	Short term notes payable	-	ū
Expenditures reimbursable by research grants and awards	9,687	10,668	Accounts payable	61,815	77,636
Inventory and other current assets	86,836	53,470	Accrued expenses	169,312	159,684
Current portion of assets limited as to use	10,976	27,735	Due to affiliates	0	0
Short term investments	591,176	371,327	Interco payable TU-other	91,688	24,824
Current portion of self-insurance assets	11,280	8,070	Current portion of accrued retirement benefits	0	0
			Current portion of estimated retroactive adjustments, third-		
			party payor	66,292	99,784
			Current portion of self-insurance program liability	58,560	55,350
Total current assets	1,726,445	1,362,361	Unexpended research grants and awards	2,278	4,198
			Other current liabilities	156,593	111,194
			Total current liabilities	624,070	545,685
Total assets limited as to use, less current portion	167,703	174,580			
Property, plant and equipment, net	296,716	287,885	Long term debt	446,036	462,779
Right of use operating lease assets	20,072	21,382	Long term due to affiliate	0	0
Long term investments	144,733	74,537	Right of use operating lease obligations	16,838	17,974
Due from affiliaties	0	0		•	-
Self insurance assets	38,883	43,024	Estimated retroactive adjustments, third-party - payors	0	30,356
Estimated retroactive adjustments, third-party-payors	0	0	Self-insurance program-liability	223,687	243,754
Goodwill and other intangibles, less accumulated	4 555	0.700	Liability for insurance - non Temple University	2,586	0
amortization	4,555	2,768	Unfunded accumulated retirement benefits	(880)	166
Beneficial interest in perpetual trusts Beneficial interest in the assets held by Episcopal	49,383	46,185	Other long-term liabilities	144,924	112,130
Foundation	32,490	32,490	Total liabilities	1,457,261	1,412,844
Beneficial interest in the Fox Chase Cancer Center	- ,	,	NET ASSETS:		
Foundation	57,410	63,336	Without Donor Restrictions	920,463	603,239
Other assets	28,827	92,590	With Donor Restrictions	189,493	185,056
			Total net assets	1,109,956	788,294
			TOTAL LIABILITIES AND NET ASSETS	2,567,217	2,201,138
TOTAL ASSETS	2,567,217	2,201,138			

Temple University Health System Obligated Group Financial Summary (Unaudited) For the nine months ended March 31, 2022

Temple University Health System Obligated Group Consolidated Statement of Operations (unaudited) (In Thousands)

For the nine months ended March 31, 2022

U	NAUDITED
CON	FIDENTIAL

Net patient service revenue: Inpatient 685,97 688,594 (2,596) Outpatient 623,97 582,752 41,75 Physician revenue 33,528 33,391 317 Commonwealth reimbursement 302,746 171,900 130,756 Net patient service revenue before provision for doubtful accounts 1,646,198 1,747,727 169,471 Provision for doubtful accounts 1,646,198 1,747,727 680 Total Net Patient Service Revenue 1,646,111 1,476,660 170,151 Research Revenue 29,444 31,851 (2,397) Population Health 11,683 26,008 (14,324) Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 311 (55) Total Revenues - F/S 13,851 (55) Total Revenues - Revenue 257 311 (55) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,566) Faculty support 102,646 36,571 (56,075) Genome of the services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (17,50) Utilities 14,673 15,414 740 Leases 11,684 10,287 (13,96) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (87,770) Linerest 17,022 17,536 514 Assessment Programs 44,057 43,699 (38,88) Operating Income(Loss) 1,680,439 1,680,439 (14,432) Operating Income(Loss) 1,680,439 1,680,439 (14,432) Other investment income 1,580,400 1,580 (14,432) Other investment income 1,580 1,580 (14,432) Other investment income 1,58		Actual	Budget	Variance
Inpatient 685,997 688,594 (2,596) Outpatient 623,927 582,752 41,175 Physician revenue 33,528 33,391 137 Commonwealth reimbursement 302,746 171,990 130,756 Net patient service revenue before provision for doubtful accounts 613 677 680 Total Net Patient Service Revenue 1,646,811 1,476,600 170,151 Research Revenue 29,454 31,851 (2,397) Population Health 11,683 26,008 (14,324) Contribution Revenue 3,111 3,888 (787) Other Revenue - F/S 67,340 41,276 26,668 Investment Income - Revenue 2,57 311 5,55 Total Revenues 643,781 611,755 (32,027) Expenses 2,57 311 5,55 Total Revenues 1,58,000 178,665 178,665 Expenses 4,54 611,755 (32,027) Employee benefits 1,22 3,41 65,966<	REVENUES:			
Outpatient 623,927 582,752 41,175 Physician revenue 33,28 33,391 137 Commonwealth reimbursement 1,646,198 1,767,27 169,471 Net patient service revenue before provision for doubtful accounts 613 (67) 680 Total Net Patient Service Revenue 29,454 31,851 2,397 Population Health 11,683 26,008 (14,324) Contribution Revenue 3,111 3,888 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 311 (55) Total Revenues - F/S 1,758,656 1,580,004 178,652 EXPENSES: 257 311 (55) Employee benefits 112,343 178,168 5,825 Professional fees 43,067 37,471 (5,56) Faculty support 383,764 37,465 9,088 Purchased services and other expense 192,310 134,251 1,942 Maintenance 19,38	Net patient service revenue:			
Physician revenue 33,528 33,911 137 Commonwealth reimbursement 30,2746 171,990 130,756 Net patient service revenue before provision for doubtful accounts 1,646,198 1,476,277 169,471 Provision for doubtful accounts 6133 (67) 680 Total Net Patient Service Revenue 29,454 31,851 (2,397) Population Health 11,683 26,008 (14,324) Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 311 (55) Total Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 1,758,655 1,580,000 178,655 Salaries 643,781 611,755 (32,027) EXPENSES: 2 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758,655 1,758	Inpatient	685,997	688,594	(2,596)
Commonwealth reimbursement 302,746 171,990 130,756 Net patient service revenue before provision for doubtful accounts 1,646,198 1,476,727 169,477 Provision for doubtful accounts 613 (67) 680 Total Net Patient Service Revenue 29,454 31,851 (2,397) Population Health 11,683 26,008 (1,432) Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 311 (55) Total Revenues 257 311 (55) Total Revenues 43,781 611,755 (32,027) Total Revenues 843,781 611,755 (32,027) EXPENSES 8 43,781 611,755 (32,027) Expelose benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Supplies and pharmaceuticals 38,374 374,665 (9,098) Purchased services	Outpatient	623,927	582,752	41,175
Net patient service revenue before provision for doubtful accounts 1,646,198 1,476,727 169,471 Provision for doubtful accounts 613 (67) 680 Total Net Patient Service Revenue 1,646,811 1,76,660 170,151 Research Revenue 29,454 31,851 (2,397) Population Health 11,683 26,008 (14,324) Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 311 (55) Total Revenues 1,758,656 1,580,004 178,655 EXPENSES: 1,758,656 1,580,004 178,655 Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 10,246 36,571 (66,075) Supplies and pharmaceuticals 333,764 374,665 (9,998) Purchased services and other expense 19,530 17,780 (1,750) Util	Physician revenue	33,528	33,391	137
Provision for doubtful accounts 613 (67) 680 Total Net Patient Service Revenue 1,646,811 1,476,660 170,151 Research Revenue 29,454 31,851 (2,397) Population Health 111,683 26,008 (14,324) Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,008 Investment Income - Revenue 257 311 (55) Total Revenues 257 311 (55) EXPENSES: 843,781 611,755 (32,027) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Utilities 13,653 15,414 740 Leases 11,667 35,904 (877)	Commonwealth reimbursement	302,746	171,990	130,756
Total Net Patient Service Revenue 1,646,811 1,746,660 170,151 Research Revenue 29,484 31,851 (2,397) Population Health 11,683 26,008 (14,324) Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 311 (55) Total Revenues 1,758,656 1,580,004 178,652 EXPENSES: 8 643,781 611,755 (32,027) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287	Net patient service revenue before provision for doubtful accounts	1,646,198	1,476,727	169,471
Research Revenue 29,454 31,851 (2,397) Population Health 11,683 26,008 (14,324) Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 311 (55) Total Revenues 1,586,065 1,580,004 178,652 EXPENSES: 8 48,781 611,755 (32,027) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 38,003 32,606 (6,197) Depreciation and amortization 38,003 32,606 (6,197) Interest 17,022 17,536 <	Provision for doubtful accounts	613	(67)	680
Population Health 11,683 26,008 (14,324) Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 41,276 26,064 Investment Income - Revenue 257 41,276 26,062 Total Revenues 1,758,656 1,580,004 178,652 EXPENSES: 8 643,781 611,755 32,0227 Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 19,330 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 11,684 10,287 (1,396) Insurance 38,003 32,606 (6,197) Depreciation and amortization 36,761 35,904 <td>Total Net Patient Service Revenue</td> <td>1,646,811</td> <td>1,476,660</td> <td>170,151</td>	Total Net Patient Service Revenue	1,646,811	1,476,660	170,151
Contribution Revenue 3,111 3,898 (787) Other Revenue - F/S 67,340 41,276 26,064 Investment Income - Revenue 257 311 (55) Total Revenues 1,758,656 1,580,004 178,652 EXPENSES: 843,781 611,755 (32,027) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514	Research Revenue	29,454	31,851	(2,397)
Other Revenue - F/S Investment Income - Revenue 67,340 (20,000	Population Health	11,683	26,008	(14,324)
Investment Income - Revenues 257 311 (55) Total Revenues 1,758,656 1,580,004 178,652 EXPENSES:	Contribution Revenue	3,111	3,898	(787)
Total Revenues 1,758,656 1,580,004 1778,652 EXPENSES: 30 d 43,781 611,755 (32,027) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319	Other Revenue - F/S	67,340	41,276	26,064
EXPENSES: Salaries 643,781 611,755 (32,027) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non	Investment Income - Revenue	257	311	(55)
Salaries 643,781 611,755 (32,027) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Excess of fair value of net assets acquired over consideration paid 0 0	Total Revenues	1,758,656	1,580,004	178,652
Salaries 643,781 611,755 (32,027) Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Excess of fair value of net assets acquired over consideration paid 0 0	EXPENSES:			
Employee benefits 172,343 178,168 5,825 Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0		643.781	611.755	(32.027)
Professional fees 43,067 37,471 (5,596) Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 329,157 1,030<	Employee benefits	•	•	` ' '
Faculty support 102,646 36,571 (66,075) Supplies and pharmaceuticals 383,764 374,665 (9,098) Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 <td>·</td> <td>43,067</td> <td>•</td> <td></td>	·	43,067	•	
Purchased services and other expense 132,310 134,251 1,942 Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 329,157 1,030 238,127 Net Income (Loss) from Discontinued Operations 0 0 0 0	Faculty support	102,646	36,571	
Maintenance 19,530 17,780 (1,750) Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0 0	Supplies and pharmaceuticals	383,764	374,665	(9,098)
Utilities 14,673 15,414 740 Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) from Discontinued Operations 0 0 0 0	Purchased services and other expense	132,310	134,251	1,942
Leases 11,684 10,287 (1,396) Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) from Discontinued Operations 0 0 0 0	Maintenance	19,530	17,780	(1,750)
Insurance 38,803 32,606 (6,197) Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) from Discontinued Operations 0 0 0 0	Utilities	14,673	15,414	740
Depreciation and amortization 36,761 35,904 (857) Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0	Leases	11,684	10,287	(1,396)
Interest 17,022 17,536 514 Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) from Discontinued Operations 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0 0	Insurance	38,803	32,606	(6,197)
Assessment Programs 44,057 43,699 (358) TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0	Depreciation and amortization	36,761	35,904	` ,
TOTAL EXPENSES 1,660,439 1,546,106 (114,333) Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0	Interest	•	•	
Operating Income(Loss) 98,217 33,898 64,319 Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0	Assessment Programs	44,057	43,699	(358)
Other investment income (7,990) 9,655 (17,645) Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0	TOTAL EXPENSES	1,660,439	1,546,106	(114,333)
Excess of fair value of net assets acquired over consideration paid 0 0 0 Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0	Operating Income(Loss)	98,217	33,898	64,319
Non operating income (loss) 239,157 1,030 238,127 Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0	Other investment income	(7,990)	9,655	(17,645)
Net Income (Loss) 329,385 44,583 284,801 Income (Loss) from Discontinued Operations 0 0 0	Excess of fair value of net assets acquired over consideration paid	0	0	0
Income (Loss) from Discontinued Operations 0 0 0	Non operating income (loss)	239,157	1,030	238,127
	Net Income (Loss)	329,385	44,583	284,801
Net Income (Loss) after Discontinued Operations 329,385 44,583 284,801	Income (Loss) from Discontinued Operations			0
	Net Income (Loss) after Discontinued Operations	329,385	44,583	284,801

Temple University Health System Obligated Group Consolidated Statement of Operations (unaudited) (In Thousands) For the nine months ended March 31, 2022

UNAUDITED CONFIDENTIAL

	Actual	Budget	Variance
OTHER CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS:			
Unrestricted unrealized gain/loss	(9,595)	0	(9,595)
Net asset released from restriction used for purchase of PPE	905	0	905
Transfers from (to) affiliates	(1,102)	(1,103)	0
Interfund Transfer	0	0	0
Other comprehensive income pension	242	0	242
TOTAL INCREASE (DECREASE) IN NET ASSETS WITHOUT DONOR RESTRICTIONS	319,834	43,481	276,353
NET ASSETS WITH DONOR RESTRICTIONS			
Contribution income	11,240	0	11,240
Net assets released from restrictions	(4,579)	0	(4,579)
Net change in fair value of investments	(425)	0	(425)
Interfund Transfer	0	0	0
Investment income (loss)	3,405	0	3,405
Change in value of beneficial interests	(5,204)	0	(5,204)
TOTAL INCREASE (DECREASE) IN NET ASSETS WITH DONOR RESTRICTIONS	4,437	0	4,437
TOTAL INCREASE (DECREASE) IN NET ASSETS	324,271	43,481	280,790
· · · · · · · · · · · · · · · · · · ·			

Temple University Health System Obligated Group Balance Sheet (In Thousands) March Fiscal Year 2022

	March FY22	June FY21		March FY22	June FY21
ASSETS			LIABILITIES and NET ASSETS:		
CURRENT ASSETS:			CURRENT LIABILITIES:		
Cash and cash equivalents	360,547	455,762	Current portion of long-term debt	17,508	12,975
Patient accounts receivable, net	252,686	246,733	Lines of credit	0	0
Other receivables, including current portion pledges	279,134	83,995	Cash overdraft	0	0
Due from affiliates - Short term	23,161	34,440	Short term notes payable	0	0
Due from Temple University	1,056	1,570		-	v
Expenditures reimbursable by research grants and awards	9,687	10,668	Accounts payable	59,960	75,624
Inventory and other current assets	84,498	52,930	Accrued expenses	154,350	149,045
Current portion of assets limited as to use	9,641	20,996	Due to affiliates	21,309	39,649
Short term investments	559,099	338,931	Interco payable TU-other	90,544	24,824
Current portion of self-insurance assets	11,280	8,070	Current portion of accrued retirement benefits Current portion of estimated retroactive adjustments, third-	0	0
			party payor	66,292	99,784
-	4 500 700	4.054.005	Current portion of self-insurance program liability	27,034	23,823
Total current assets	1,590,790	1,254,095	Unexpended research grants and awards	2,278	4,198
			Other current liabilities	151,509	109,865
			Total current liabilities	590,784	539,786
Total assets limited as to use, less current portion	89,586	87,446			
Property, plant and equipment, net	294,158	285,276	Long term debt	446,020	462,748
Right of use operating lease assets	19,709	20,827	Long term due to affiliate	0	0
Long term investments	136,736	67,098	Right of use operating lease obligations	16,634	17,675
Due from affiliaties	0	0	Estimated retroactive adjustments, third-party - payors	0	30,356
Self insurance assets	38,883	43,024		-	,
Estimated retroactive adjustments, third-party-payors Goodwill and other intangibles, less accumulated	0	0	Self-insurance program-liability Liability for insurance - non Temple University	125,273 2,586	140,240 0
amortization	4,555	2,768	Unfunded accumulated retirement benefits	(1,892)	(1,606)
Beneficial interest in perpetual trusts	49,383	46,185	Other long-term liabilities	141,873	109,223
Beneficial interest in the assets held by Episcopal Foundation	32,490	32,490	Total liabilities	1,321,279	1,298,422
Beneficial interest in the Fox Chase Cancer Center	32,490	32,490	NET ASSETS:		· · · · · ·
Foundation	57,410	63,336	Without Donor Restrictions	866,374	546,540
Other assets	63,445	127,471	With Donor Restrictions	189,493	185,056
		<u> </u>		1,055,867	731,596
			Total net assets		
			TOTAL LIABILITIES AND NET ASSETS	2,377,145	2,030,017
TOTAL ASSETS	2,377,145	2,030,017			